The Collaboration for Oncology Data in Europe (CODE) sponsors the Value of Data in Oncology Conference on 5 June, Bucharest, Romania

Read More

Dr. Ashley Woolmore, Senior Vice President, Head of European Data and Evidence Networks, and CODE Lead at IQVIA will be speaking at the Value of Data in Oncology conference in Bucharest, Romania on 5 June 2019 which CODE is also sponsoring.  This conference is being held in the context of the Romanian EU Council Presidency.

Organised by the Centre for Innovation in Medicine, the event’s goal is to define a new vision for strategies that tackle cancer and support the objectives set out by the European Commission. These objectives were defined by Martin Seychell, Deputy Director-General for Consumers and Health: “By boosting research and cooperation, we can ensure that efficient treatments are developed to treat cancer patients across the EU…[and] by raising awareness about cancer prevention our ambitious goal is to reduce new cancer cases by 15% by 2020”1. The Centre for Innovation in Medicine will be proposing the development of an EU cancer plan focused on “data”, “technologies” and “human intelligence”.

“There is an increasing need to focus efforts at a European level to tackle the rising incidence of cancer. With this event, the Centre for Innovation in Medicine aims to bring the oncology community together and develop a next-level digital approach to meeting the goals of the European Commission.” – Marius Geanta, President and Co-Found at the Centre for Innovation in Medicine

Dr. Woolmore has been invited to speak as a panellist on the topic of “Capturing the real perspective on cancer in the healthcare systems across Europe.” He will be sharing CODE’s vision of addressing key challenges in the oncology community by providing near real-time data at scale. He will also describe why we have chosen to build the Oncology Data Network (ODN) to support this vision by providing access to high quality clinical data which is analytically available for research.

 “Part of the value of data in oncology comes from the actionability of insights drawn from a systematic and large-scale collaborative network. These insights have greater power to inform quality, innovation and value in cancer care if they are describing ‘today’s treatment’. Understanding where we are today can help us shape cancer care in the future.  I am delighted to have an opportunity to contribute to this important discussion and support this event.” – Dr. Ashley Woolmore, Senior Vice President, Head of European Data and Evidence Networks, and CODE Lead at IQVIA

To learn more about how our work with CODE and the ODN are aligned with EU cancer objectives, please contact Julia Levy,

  1. Seychell, Martin. “Cancer.” Health-EU Newsletter 122 – Focus: Cancer, European Commission,

Belgian radio station, RTBF, reports on the first Belgium clinic joining the Oncology Data Network

Read More

The Collaboration for Oncology Data in Europe (CODE) and the Oncology Data Network have received coverage on Belgian radio station, RTBF. The broadcast on 24 April 2019 focused on the Clinique Saint-Luc Bouge in the Namur region of Belgium.

The Saint-Luc Clinic is the first cancer treatment centre in Belgium to join the Oncology Data Network (ODN). In the radio broadcast, Anaïs Stas, RTBF journalist, reports on an interview with Dr Marie Mailleux, a Medical Oncologist at Clinique Saint-Luc Bouge, explaining what motivated the Clinic to join the ODN.

Visit the RTBF website for more information.

Alternatively, please click here to read the radio transcript translation in English.

CODE featured in Belgian newspaper, L’Echo

Read More

The Belgian newspaper, L’Echo has published an article featuring the Collaboration for Oncology Data in Europe (CODE) and the Oncology Data Network initiative. The article, published on 23 April 2019, is entitled “Hospitals to share data on cancer treatment” (“Les hôpitaux vont partager les données sur le traitement des cancers”).

Dr. Didier Vander Steichel, Director General of the Belgian Cancer Foundation (Fondation contre le Cancer/ Stichting tegen Kanker) was interviewed by healthcare journalist Jean-Paul Bombaerts for this article. Dr Vander Steichel is a member of the CODE Country Advisory Group for Belgium which launched in December 2018. The article sets out opportunities and challenges for CODE moving forward.

Read the full article on the L’Echo website.

Alternatively, please click here to read the article in French or here for the English version.

One hundred hospitals and growing: the Oncology Data Network celebrates major milestone

Read More

The Oncology Data Network (ODN), a pioneering collaborative network for European cancer treatment centres, has reached an important milestone. The Network has now grown to 100 hospitals across six countries. The centres involved in the Network are providing cancer treatment to some 60,000 people with cancer. This strong growth has been accomplished since the initiative was launched at the European Society for Medical Oncology Congress (ESMO) 2017.

The Oncology Data Network is open to all centres who are treating cancer patients and its aim is to become an invaluable resource for the European cancer community. In line with that goal, the near-term ambition is for the Network to double in size in the next 12 months.

The value of the Oncology Data Network increases as the number of centres who are joining increases. As one of the ODN members, Dr Enrique Grande, Head of the Medical Oncology Service at MD Anderson Hospital in Spain said,

“Undoubtedly, initiatives such as the ODN help to improve the quality of care in cancer treatment and are a great step forward in terms of innovation.”

Ashley Woolmore, who is leading the ODN initiative added,

“This is a significant achievement and we give our sincere thanks to the 100 centres who have joined the Network. This would not have been possible either without the help of our international clinical advisors on the Clinical and Analytical Steering Group, the members of our Country Advisory Groups as well as each and every person involved in CODE.

If you are interested in joining the ODN, please contact us.

100 Network members and growing

ECCO-CODE roundtable report “Building the Roadmap to Outcomes-Based Cancer Care” now available online

Read More

Today the European CanCer Organisation (ECCO) and the Collaboration for Oncology Data Europe (CODE) publish the report of the ECCO-CODE Roundtable “Building the Roadmap to Outcomes-Based Cancer Care”. The aim of the event was to examine the opportunities from outcomes-based healthcare to improve cancer care, building on the findings of the ECCO-CODE joint research project on pragmatic outcomes measurement (POM).

The jointly published roundtable report, “Building the Roadmap to Outcomes-Based Cancer Care”,  reflects the discussions between key stakeholder groups present including representatives from patient organisations, clinicians, biopharmaceutical and medical devices industry representatives and associations, and policy makers.

The meeting concluded with recommendations including:

  1. A call for coordination of innovation across oncology stakeholders to build a focused approach to achieving systematic outcomes measurement
  2. A call for data infrastructures to support near-real time delivery of information back to healthcare systems 
  3. A recommendation for direct engagement with payers on pragmatic outcome acceptability 
  4. Encouragement for an Essential Requirements, or other exercise, examining how to achieve routine capture of pragmatic outcomes measures
  5. A call for a co-ordinated approach to the capture of patient reported data to allow inter-centre and inter-national comparability
  6. Encouragement for further dialogue, debate and exchange between stakeholders on the matters raised at the meeting and in the ECCO-CODE report ‘Understanding Pragmatic Outcome Measures in Oncology’.

“Today we learned about the importance of the speed of providing information back to healthcare systems to inform quality feedback loops and learning systems. We heard about the importance of having all of the relevant stakeholders working together and the value and complexities of patient reported data. We agreed that now is the time to coordinate the huge amount of innovation being done in this space.” – Dr Ashley Woolmore, CODE Lead and Senior Vice President, Real World and Analytics Solutions Global Team, Head of European Data and Evidence Networks, IQVIA

“The discussion today has been very fruitful.  When we think about data collection today, it is necessary is to have communication that reflects these issues and not just issues around the doctors but those around the whole team. The take home message from this discussion about pragmatic outcomes measurement is not at the end, it is in the middle. We need to bring in all relevant stakeholders, to ensure the full picture of cancer is painted.” – Professor Klaus Meier, Chair of the ECCO Oncopolicy Committee and ESOP President.

Read more about the ECCO-CODE project here

Read more about the ECCO-CODE roundtable here

The Belgian Oncology Nurses Association (SIO) announce collaboration with the Collaboration for Oncology Data in Europe (CODE)

Read More

To read this post in French, please see below the English post.

The Belgian Oncology Nurses Association (Société des Infirmières en Oncologie, SIO) has today announced a collaboration with the Collaboration for Oncology Data in Europe (CODE).

“Oncology Nurses play a critical role in patient care. As key members of multi-disciplinary teams, we are often on the front line of both capturing but also using information on cancer treatment to help us optimise the care and support we provide to patients.  We are therefore delighted to be partnering with CODE. We support their goal of creating a network of centres around Europe that enable the sharing of information on how anti-cancer medicines are actually being used in clinical practice. We are looking forward to working with CODE to help realise this vision,” said Patrick Crombez, President of SIO, Head Nurse of the Haematology Department and responsible for research and nursing development at the Institut Jules Bordet and Board Member of the European Oncology Nursing Society (EONS) as well as Ayhan Findink, Head of External Relations at the SIO and Maitre-assistant the Institut Parnasse-ISEI and member of the CODE Country Advisory Group which provides country level governance for the CODE initiative.

“The creation of the Oncology Data Network is an ambitious and challenging initiative,” added Myriam Guiral, CODE’s Country Lead in Belgium.  “To succeed with both creating the network and realising its full value to help inform patient care and address the challenges of financial sustainability, it is critical to work with key stakeholders from across the cancer community.  The collaboration with SIO offers an exciting platform on which we are looking forward to building by bringing together players from patient organisations, professional bodies and policy makers and influencers.

The collaboration will be launched officially at an event in Brussels on 4 December 2018. For more information on the project, please contact Ayhan Findik at or Myriam Guiral at

Collaboration avec CODE

La Société des infirmières en oncologie (SIO) a annoncé aujourd’hui une collaboration avec CODE :

« Les infirmières en oncologie jouent un rôle essentiel dans les soins aux patients. En tant que membres clés des équipes multidisciplinaires, nous sommes souvent en première ligne pour la saisie mais aussi pour l’utilisation d’informations sur le traitement du cancer afin de nous aider à optimiser les soins et le soutien que nous fournissons aux patients. Nous sommes donc ravis de nous associer à CODE. Nous soutenons leur objectif de créer un réseau de centres en Europe permettant le partage d’informations sur la manière dont les médicaments anticancéreux sont réellement utilisés dans la pratique clinique. Nous sommes impatients de travailler avec CODE pour concrétiser cette vision « , ont déclaré Patrick Crombez, président de la SIO et infirmier en chef du département d’hématologie et chargé de la recherche & du développement infirmier à l’Institut Jules Bordet et membre du conseil de l’EONS (European Oncology Nursing Society) ainsi que Mr Ayhan Findik, membre de la Gouvernance locale pour ODN en Belgique et responsable des relations extérieures à la SIO et Maitre-assistant à l’institut Parnasse-ISEI.

« La création du réseau de données en oncologie est une initiative ambitieuse et nécessaire « , a ajouté Myriam Guiral, responsable de CODE et la mise en place du Réseau de données en Oncologie (ODN) : en Belgique et aux Pays Bas. « Pour réussir à la fois à créer le réseau et à en tirer pleinement parti pour aider à informer les patients et à relever les défis de la viabilité financière, il est essentiel de travailler avec les principales parties prenantes de la communauté du cancer. La collaboration avec la SIO offre une plate-forme passionnante sur laquelle nous sommes impatients de construire en réunissant des acteurs issus d’organisations de patients, d’organismes professionnels, de décideurs et d’influenceurs.

La collaboration débutera officiellement lors d’un événement de lancement prévu à Bruxelles le 4 décembre 2018.

Pour plus d’informations sur le projet, veuillez contacter Monsieur Ayhan Findik à et Myriam Guiral à

Building the roadmap to outcomes-based cancer care

Read More

The European CanCer Organization and the Collaboration for Oncology Data in Europe announce a pragmatic approach to understand, evaluate, and improve clinical care in Oncology

LOCATION Vienna, Austria, DATE 7 September 2018 – Today the European CanCer Organization (ECCO) and the Collaboration for Oncology Data in Europe (CODE) announced the results of a research project which identifies a standard set of eight “pragmatic outcome measures” in cancer care that have value to both clinical teams and patients. These outcomes measures were derived from real-world data collected as part of routine care, and validated by leading clinicians and patient advocates. Their findings represent a valuable step in Europe’s move toward outcomes-based care in cancer.

The jointly published report, Understanding Pragmatic Outcome Measures in Oncology, reflects 25 interviews with stakeholders from the European oncology community including: patient representatives, clinicians and individuals from various oncologic professional bodies. The results of this project will be discussed at the ECCO 2018 Summit, the 7 to 9 September 2018, and at a roundtable in Brussels on 6 November 2018.

A key driver of the research was to build a better understanding of how health systems can move towards more outcome-based cancer care. With a focus on “pragmatic outcome measures,” the research evaluated opinions from healthcare professionals and patients regarding the value of widely available outcome measures, as well as measures which are more complex to assess. The ultimate objective of the report was to chart a path toward comprehensive outcome measurement through achievable stages.

Key findings from the research include:

  • Consensus exists on the value that widely available, systematic outcomes measurement can provide to all involved in cancer care
  • Alignment on the value to patients and clinicians of an initial set of “pragmatic outcomes measures” which can be collected relatively easily and at scale in near real time as a first step towards a part of a broader programme toward comprehensive outcome management for cancer care
  • Exploring and reconciling metrics that are currently perceived as having different value to patients and clinicians, respectively
  • The need to address practical hurdles, including capturing data in a structured and standardized manner given technology and resource limitations, and a lack of guidelines. Removing such obstacles are necessary steps toward developing an integrated approach that incorporates patient reported data into routine clinical practice
  • A call to come together at the European level to ensure that efforts to capture outcomes measures are properly resourced and prioritised
  • A call to develop and embed outcomes measurement into European-level ”essential requirements”[1]


Commenting on the findings,

ECCO President Professor Philip Poortmans said: “Outcome measurement is seen by many within the oncology community as an exciting opportunity to have a more patient-centric approach to care, and to allow healthcare providers to make informed decisions based on patient current needs and historical research. However, we need to now move the discussion beyond simple expression of aspiration and into the practicalities of execution. The results of this research provide excellent insights for decision makers about the next steps in the journey towards comprehensive outcome measurement” 

Professor David Kerr, Head of Oncology at the University of Oxford and Chair of CODE’s Clinical and Analytical Steering Committee added: “This research provides clarity about immediate opportunities to enable the European cancer community to improve understanding of the value of treatment interventions. Harnessing the insights that are available to us today, will enable us to better inform decisions and contribute to the advancement of cancer care. Pragmatic outcomes measures are an actionable immediate first step towards widespread collection and use of comprehensive outcomes measurement in the European oncology community. The recommendations in this report also set out a clear roadmap where increased focus and investment in the near term will allow us to gain further insight and work together towards a comprehensive, longer-term approach. ”




  1. The European CanCer Organisation (ECCO) is a not-for-profit federation that exists to uphold the right of all European cancer patients to the best possible treatment and care, promoting interaction between all organisations involved in cancer at European level. Through its 23 Member Societies – representing over 150 000 professionals – ECCO is the only multidisciplinary organisation that connects and responds to all stakeholders in oncology Europe-wide. It does this by creating awareness of patients’ needs and wishes, encouraging progressive thinking in cancer policy, training and education and promoting European cancer research, prevention, diagnosis, treatment and quality care through the organisation of international multidisciplinary meetings. Further information here:
  2. The ECCO 2018 European Cancer Summit, will be held on 7-9 September 2018 in Vienna, Austria bringing worldwide leaders from the cancer healthcare, patient advocacy and stakeholder communities together in a unique multidisciplinary forum. Outcomes Research is one of the three topic pillars of the event. Further information here.
  3. The ECCO-CODE research project was jointly developed through open conversations and dialogue with oversight by both parties’ advisory boards: the ECCO OncoPolicy Committee Executive and the CODE Clinical and Analytical Steering Committee (CASC), whereby areas of mutual research interest were identified, and was supported via grant funding from IQVIA World Publications Limited to ECCO.
  4. The Collaboration for Oncology Data in Europe (CODE) is an initiative supporting the creation of the Oncology Data Network (ODN) that will provide reliable, up-to-date information on how anti-cancer medicines are actually itself used in clinical practice and enable flexible payment models. The ODN is a collaborative data sharing network open to any cancer treatment centres across Europe that wishes to join, to share non-identified information on how treatment centre-administered anti-cancer medicines are used in clinical practice.
  5. CODE is led by IQVIA and has been established with support from leading biopharmaceutical companies as the Biopharmaceutical Members, who joined CODE as part of their commitment to providing patients with access to innovative medicines, in a way that is financially sustainable for the payers, biopharmaceutical research and development and oncology community. The Biopharmaceutical Members are Bristol-Myers Squibb, Eli Lilly and Company, Merck, Pfizer, AstraZeneca and Amgen. To learn more, visit: 
  6. ECCO essential requirements for quality cancer care (ERQCC) are checklists and explanations of organisation and actions that are necessary to give high-quality care to patients who have a specific tumour type. They are written by European experts representing all disciplines involved in cancer care. More information here:
  7. For more information on this research project, or on the upcoming policy roundtable in November, please contact Richard Price, EU Policy Affairs Manager, ECCO, at or Julia Levy, External Engagement Lead, CODE at


New research paper “Economics of Innovative Payment Models Compared to Single Pricing of Pharmaceuticals” by OHE and Prof Richard Sullivan (King’s College London)

Read More

The Office of Health Economics (OHE) and Professor Richard Sullivan from King’s College London have published a new research paper on the “Economics of Innovative Payment Models Compared to Single Pricing of Pharmaceuticals.”   This research was supported by an unrestricted educational grant from IQVIA.

The paper explores and critiques existing academic research on the benefits and challenges of setting different value-based prices for the same medicine.  It also presents an economic analysis of the introduction of a multi-price model.  The authors go beyond the assessment of a single product to explore the impact of competition, including the longer-term impact on patient access, R&D incentives and the implications of increased competition at the indication level.  The paper concludes that the longer-term effects of indication based pricing offer optimised incentives for R&D and the potential for increased price competition at the indication-level, ultimately delivering better value to the health system.

Dr Ashley Woolmore, CODE Lead and Senior Vice President IQVIA (formerly QuintilesIMS) said, “This is a thought provoking piece of research that analyses the potential economic benefits of adopting innovative payment models.  One of the key objectives of the CODE initiative is to help enable such agreements.  We welcome this robust research as an important contribution to the ongoing policy debate.  We look forward to playing our part in facilitating the implementation of these new payment models, which are designed to help the healthcare system address the challenges of financial sustainability of cancer treatment.”

Please visit the OHE website to read the report.



The European CanCer Organisation partners with the Collaboration for Oncology Data in Europe to explore pragmatic outcomes measurement

Read More

The European CanCer Organisation (ECCO) and the Collaboration for Oncology Data in Europe (CODE) are embarking on a joint initiative to explore outcomes measurement within cancer care. The goal is to further explore the topic of outcomes measurement to identify metrics of high clinical value, meaningful for both patients and clinicians, but which can be measured efficiently and be put “at the right scale”. This work will be part of the longer journey towards comprehensive outcomes measurement. “ECCO’s mission is to improve outcomes for cancer patients through the delivery of higher quality cancer care. This partnership allows us to contribute to the debate on how to move towards delivering greater value to patients and healthcare systems. We are therefore delighted to be working with CODE to better understand which outcomes can be measured accurately today, to explore their value and the associated cost of capturing this data, and to contribute towards the journey to comprehensive outcomes measurement” said Prof Philip Poortmans, ECCO’s President.

“Innovations in the treatment of cancer are offering increased options and choices for clinicians and patients,” added David Kerr, Professor of Cancer Medicine at the University of Oxford and Chair of CODE’s Clinical and Analytical Steering Committee. “Valuable work has already been done to define comprehensive outcomes approaches for a number of cancer types by organisations such as ICHOM. However, the systematic evaluation of outcomes that can be generated from the day-to-day clinical setting, particularly outcomes that matter to patients, is still at an early stage due to the complexity of cancer and cancer care. We look forward to working with ECCO on this important project.”

The research project will explore the value of different outcome metrics, while assessing the clinical insight that can be derived and the feasibility, complexity and challenges associated with sourcing the required information. It also aims to help inform the understanding of the drivers and challenges of information gathering for outcomes based health systems and recognise what can be achieved with existing real-world datasets.

ECCO and CODE will be capturing insights from interviews with a wide range of stakeholders from various organisations within the European oncology community to ensure that a wide range of views is included in the project. The interviews will be analysed and contribute to a report developed by ECCO and CODE. This will then offer an opportunity for broader engagement and discussion of the research findings, along with additional perspectives on pragmatic outcomes measurement, at the ECCO 2018 European Cancer Summit from 7-9 September 2018.

For more information on the project, please contact Richard Price, EU Policy Affairs Manager, ECCO, at or Julia Levy, External Engagement Lead, CODE at .

CODE sponsors the Value Based Healthcare Prize 2018, blog published

Read More

CODE is delighted to sponsor the Value Based Healthcare Prize (VBHC) 2018. The VBHC Prize rewards and recognises initiatives that have adopted a new line of thinking in creating excellent patient value in terms of outcomes and costs. The prize will be awarded at a ceremony in Amsterdam on 26th April 2018.

As part of our support, we contributed the following blog post which was published on the VBHC Prize website and in the event booklet.

A step on the journey to value based care in cancer

A key pre-requisite to a value based approach to healthcare is the availability of relevant information to inform decision making and determine the value that is being realised.

In cancer care, this has become more complex with the substantial growth in the number of new anti-cancer medicines, often for multiple indications and different combinations, sequences and other variations. These innovations offer significant potential to improve treatment for cancer patients, but they create challenges for clinicians to navigate this complexity. At the same time, ensuring access to these new innovations can also generate challenges of financial sustainability for healthcare systems.

Sharing real-world insights in oncology

To address these challenges, up-to-date information on the use of anti-cancer drugs in clinical practice is vital. This is the impetus behind the establishment of the Collaboration for Oncology Data in Europe (CODE), led by IQVIA with support from leading biopharmaceutical companies. CODE is supporting the creation of the Oncology Data Network (ODN), which aims to provide timely information back to the healthcare system about anti-cancer medicines use for all patients who are actually being treated, from all treatment centres who choose to join.
The ODN is a network of cancer treatment centres that will share non-identified information on how anti-cancer medicines are used in their clinical practice with the Network. Treatment centres who wish to join the ODN will be provided with the analytical tools to explore how they treat their patients and compare this against multi-centre aggregated information from across the Network. This information could be used to consider ways to help inform patient care and identify variation in their use of anti-cancer medicines across Europe.

Informing decision making and enabling better value care in cancer

The information derived from the ODN can also provide an important contribution to the development of new kinds of flexible payment agreements based on real-world usage of anti-cancer medicines. The information on medication use is intended to support agreements that better align payment to the clinical benefit of these medicines.

The creation of the network is a step towards gaining insights into a value-based approach in the use of innovative anti-cancer medicines, whilst providing healthcare systems across Europe with up-to-date information to help inform patient care.

To learn more about the Collaboration for Oncology Data in Europe, visit For further enquiries, email us at